1.
JAMA
; 330(15): 1493-1494, 2023 10 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37847275
2.
JAMA
; 330(15): 1492-1493, 2023 10 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37847278
3.
JAMA
; 329(22): 1913-1914, 2023 06 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37204810
RESUMO
This Viewpoint discusses the long-term medical, emotional, and financial implications of using amnioinfusion to treat anhydramnios; outlines the ongoing Renal Anhydramnios Fetal Therapy (RAFT) trial, which aims to document outcomes and survival in infants after amnioinfusion; and suggests that amnioinfusions be withheld in early anhydramnios, pending the findings of the RAFT trial.